Hyftor 0.2% topical gel is supplied in 10 gram tubes containing 2mg of sirolimus per gram; it is available through a limited network of specialty pharmacies. Hyftor ™ (sirolimus topical gel) is now ...

The FDA approved sirolimus 0.2% gel (Hyftor) as the first topical treatment for facial angiofibroma associated with tuberous sclerosis complex (TSC), Nobelpharma announced. The approved indication ...

Credit: FDA. The approval was based on data from a phase 3 trial that assessed Hyftor in 62 patients with facial angiofibroma associated with TSC. The Food and Drug Administration (FDA) has approved ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved topical Hyftor for the treatment of facial angiofibroma in patients who have tuberous sclerosis ...

Nobelpharma America is launching FACE FORWARD, a website focused on education and awareness of a rare disease known as facial angiofibroma, which is an aspect of tuberous sclerosis complex (TSC). The ...

We report on 25 additional cases of CAF to widen the clinicopathological features with an additional morphologically sarcomatous transformed case, and underpin the genetic relationship with ...

Juvenile angiofibroma (JA), a rare tumour developing in adolescent and young adult males, accounts for 0.05-0.5% of all head and neck tumours [1]. Juvenile angiofibroma is composed of histologically ...

Juvenile nasopharyngeal angiofibroma (JNA) is a rare, benign tumor. JNA tumors contain many blood vessels and are called benign vascular tumors. They usually grow deep in the sinonasal cavity (nose ...